TapImmune Inc. To Provide Update On And Confirmation Of Phase II Clinic Trial Initiation
SEATTLE, Sept. 10, 2015 /PRNewswire/ -- TapImmune, Inc. (OTCQB: TPIV), a clinical stage cancer immunotherapy company will hold a conference call on Wednesday, September 16 at 11:00 AM EDT to discuss recent progress in its clinical programs and financing.
Following recent announcements on TapImmune signing an exclusive licensing agreement with the Mayo Foundation for Medical Research & Education for the Folate Receptor Alpha technology, and the transfer of the IND from Mayo to TapImmune, the structure and timing of the Phase II clinical programs, and the current status of capital to progress through Phase II trials will be reviewed.
The conference call (http://services.choruscall.com/links/tpiv150916) is scheduled for Wednesday September 16 at 11:00 AM EDT
PARTICIPANT TELEPHONE NUMBERS | |||
PARTICIPANT DIAL IN (TOLL FREE): | 1-866-652-5200 | ||
PARTICIPANT INTERNATIONAL DIAL IN: | 1-412-317-6060 | ||
Participants should ask to be joined into the TapImmune, Inc. call. | |||
CONFERENCE REPLAY | |||
US Toll Free: | 1-877-344-7529 | ||
International Toll: | 1-412-317-0088 | ||
Canada Toll Free: | 855-669-9658 | ||
Replay Access Code: | 10072345 | ||
End Date: Dec 18, 2015 | |||
To access the replay using an international dial-in number, please select the link below. | |||
Available 1 hour after the end of the conference. | |||
===========================================================
About TapImmune Inc.
TapImmune Inc. is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company's website at www.tapimmune.com for details.
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.
CONTACTS:
TapImmune Inc.,
Glynn Wilson, Ph.D.
Chairman & CEO
(866)-359-7541
PCG Advisory
Kirin M. Smith
Chief Operating Officer
+1-(646)-863-6519
Sean Leous
Chief Communications Officer
+1-(646) 863-8998
www.pcgadvisory.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tapimmune-to-provide-update-on-and-confirmation-of-phase-ii-clinic-trial-initiation-300140867.html
SOURCE TapImmune, Inc.
Help employers find you! Check out all the jobs and post your resume.